Free Daily Podcast Summary
EHA Unplugged: Daily Summaries Delivered
by European Hematology Association
In these EHA-produced podcasts, experts share with you their hematology knowledge and stories. With "EHA Unplugged" we would like to give you the opportunity to unplug from your computer screen, while still learning, by listening to interviews, clinical cases, monologues, and more.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 2 weeks ago14 min
How Experts Treat Chronic Lymphocytic Leukemia (CLL)
Explore the latest EHA guidelines on chronic lymphocytic leukemia (CLL) and Richter transformation with key guideline authors Prof Barbara Eichhorst, hematologist at University Hospital Cologne (Germany), and Prof Paolo Ghia, Director of the CLL Program at Università Vita-Salute San Raffaele (Milan, Italy). For the first time, the guidelines no longer recommend chemoimmunotherapy when targeted options are available, based on two key advances: the approval of acalabrutinib plus venetoclax with or without obinutuzumab for frontline CLL, and the approval of pirtobrutinib, a non-covalent BTK inhibitor, for relapsed/refractory disease—particularly after prior covalent BTK inhibitor treatment. The guests also make clear that patient selection matters, including TP53 status, IGHV status, comorbidities, co-medications, safety profile, and patient preferences. Further, the experts highlight a landmark change in how the recommendations were developed: for the first time, patients and patient advocates participated as authors, bringing a patient-centred perspective to treatment decisions, active surveillance, and supportive care. Tune in for practical insights into personalized CLL management, fixed-duration targeted therapy, treatment sequencing, and the challenges of Richter transformation.Guests: Prof Barbara Eichhorst University of Cologne, Cologne, Germany Prof Paolo Ghia Università Vita-Salute San Raffaele, Milano, Italy Host: Isabel Olivera-Martínez, PhD, Medical Writer for EHA Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe
- 3 weeks ago12 min
How Experts Treat Hodgkin Lymphoma
Stay up to date with the latest EHA guidelines on Hodgkin lymphoma. In this episode of EHA Unplugged, key guideline authors Prof. Dennis Eichenauer and Prof. Igor Aurer discuss the evidence reshaping the management of classic Hodgkin lymphoma. The discussion highlights the guideline’s central shift: the integration of targeted therapies—brentuximab vedotin and PD-1 inhibitors such as nivolumab—into frontline treatment. The experts explain updated approaches to staging and risk assessment, PET-guided treatment in early-stage disease, BrECADD for younger patients with advanced disease, and nivolumab–AVD for older patients, alongside recommendations for relapsed or refractory disease and autologous stem cell transplantation. They also consider survivorship, late effects, and the realistic prospects for chemotherapy-free, immune-based approaches. Tune in for practical, evidence-based insights into improving outcomes while reducing long-term toxicity in Hodgkin lymphoma. Guests: Prof. Dennis Eichenauer: University of Cologne, Germany; First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, German Hodgkin Study Group, University of Cologne, Cologne, Germany Prof. Igor Aurer: University Hospital Centre Zagreb, and Medical School, University of Zagreb, Zagreb, Croatia Host: Nabil Dorkhom, MD / EHA Head of Education Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe
- Oct 2, 202614 min
How to Improve Equity and Inclusion in Hematology: EHA2026 Diversity, Equity and Inclusion Award
In this episode, Prof Gianluca Gaidano, recipient of the EHA2026 Diversity, Equity and Inclusion Award, explores how promoting equity, inclusion, and access to care has shaped his work within EHA and beyond. He reflects on educational initiatives in underrepresented regions, including Africa, the Middle East, Asia, and South America, and explains how international collaborations can help expand access to medical knowledge, advanced diagnostics, and innovative therapies. The discussion explores the difference between drug availability and true patient access, the role of education and patient advocacy in reducing disparities, and how partnerships with local hematology communities can strengthen clinical practice. Prof Gaidano also shares examples from countries such as Bangladesh, Iraq, and Albania, highlighting progress in access to diagnostics, treatments, and specialist training. Listen now for insights into how to contribute to building a more equitable future for hematology. Guest: Prof Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont and Ospedale Maggiore della Carità, Novara, Italy Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe
- Sep 25, 202620 min
Advancing Adult ALL Care in Europe: EHA2026 Clinical Excellence Award
In this episode, Professor Josep-María Ribera, recipient of the EHA2026 Clinical Excellence Award, reflects on his career dedicated to adult acute lymphoblastic leukemia (ALL) and the advances that have transformed patient outcomes. He discusses the evolution of treatment for Philadelphia chromosome-positive ALL, from poor survival rates to highly effective targeted and immunotherapy-based approaches, and explains how tyrosine kinase inhibitors, blinatumomab, and chemotherapy-sparing strategies are reshaping care. The discussion also explores the growing role of measurable residual disease (MRD) monitoring and genetic risk stratification in treatment decision-making, including identifying which patients can safely avoid allogeneic stem cell transplantation. Professor Ribera highlights the impact of collaborative research through PETHEMA, EWALL, and EHA, and shares his perspective on the future of hematology. Listen now for insights into the progress of ALL treatment and a message of optimism for patients and clinicians alike.Guest: Prof Josep-María Ribera Josep Carreras Leukemia Research Institute (IJC) and Universitat Autònoma de Barcelona, Spain Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe
- Sep 22, 202622 min
Refining Transplantation and Cellular Therapy: Insights from 2026 Young EHA Award Winner Nico Gagelmann
In this episode, Dr Nico Gagelmann, recipient of the 2026 Young EHA Award, discusses his career in stem cell transplantation and the values that have shaped his work. He explains how multidisciplinary care, patient selection, graft-versus-host disease prevention, and conditioning strategies can help improve transplant outcomes. The discussion also explores the role of real-world evidence in identifying best practices and supporting efforts to harmonize transplantation approaches across centres. Dr Gagelmann also highlights the evolving role of CAR T-cell therapy, ongoing disparities in access to innovative treatments, and the importance of collaboration, education, and knowledge sharing across countries. He reflects on building international professional communities, addressing inequalities in hematology care, and ensuring that future advances remain accessible to patients. Listen now for insights into the future of transplantation, cellular therapies, and global hematology collaboration.Guest: Dr Nico Gagelmann, Dana-Farber Cancer Institute, Boston, Massachusetts, USA, and University Medical Center Hamburg-Eppendorf, GermanyHost: Isabel Olivera-Martínez, PhD, EHA Medical Writer Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe
- Sep 18, 202621 min
What Can We Learn About AML from Clonal Haematopoiesis? | EHA 2026 Research Excellence Award
In this episode, Prof George Vassiliou, recipient of the 2026 EHA Research Excellence Award, discusses how his research has advanced our understanding of clonal haematopoiesis and its relationship to acute myeloid leukaemia (AML). He explains how blood stem cells evolve over time, why specific driver mutations promote clonal expansion, and how genetic profiles can help identify individuals at low, intermediate, or high risk of developing myeloid malignancies. The discussion also explores efforts to translate these discoveries into clinical prevention strategies. Prof Vassiliou highlights emerging risk prediction models, the development of clinics focused on clonal haematopoiesis, and ongoing work to evaluate low-toxicity interventions that could reduce disease progression. He also examines the links between clonal haematopoiesis, cardiovascular disease, immune ageing, and age-related health outcomes, offering insights into the future of early detection and preventive approaches in haematology. Listen now for perspectives on how understanding clonal haematopoiesis may help reshape the prevention of AML and other age-related diseases. Guest: Prof George Vassiliou, Department of Haematology and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe
- Sep 15, 202621 min
Improving MPNs management: EHA2026 Lifetime Achievement Award
In this episode, EHA 2026 Lifetime Achievement Award recipient Prof Claire Harrison reflects on a career dedicated to advancing the understanding and management of myeloproliferative neoplasms (MPNs). She reviews the major scientific and clinical developments she has witnessed over more than two decades, including the discovery of JAK2, MPL and CALR mutations, the evolution of diagnostic criteria, and the emergence of targeted therapies for MPNs. The discussion explores landmark studies that helped shape current clinical practice, including PT-1, COMFORT-II and MAJIC-PV, as well as the growing role of patient advocacy in driving research and improving care. Prof Harrison also looks ahead to the next generation of therapies, including CALR-targeted immune approaches and combination treatment strategies, while highlighting the challenges and opportunities that remain for patients with MPNs. Listen now for insights from one of the leading figures in the field.Guest: Prof Claire Harrison Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe
- Sep 9, 202617 min
CAR T Toxicities in Focus: What We Have Learned from Registry Data
In this episode, Dr Annalisa Ruggeri discusses how registry data are helping clinicians better understand, monitor and manage CAR T-related toxicities. She explains how insights from more than 16,000 patients recorded in the European Bone Marrow Transplant Registry (EBMT), have helped improve early toxicities such as cytokine release syndrome (CRS) and ICANS awareness and management as well as helped recognise and address longer-term effects. She further explores the growing understanding of immune effector cell-associated hematotoxicity (ICAHT) and the importance of risk prediction and early intervention. Dr Ruggeri also discusses emerging safety questions as CAR T use expands, including secondary malignancies, long-term immune effects, and fertility outcomes. She highlights encouraging registry findings showing that fertility recovery and successful pregnancies are possible after CAR T therapy, offering renewed hope for patients seeking to return to normal life following treatment. Listen now for valuable insights into how registries, collaboration and long-term follow-up are helping improve cellular therapy.Guest: Dr Annalisa Ruggeri Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy Chair of the Cellular Therapy and Immunobiology Working Party (Education Portfolio), EBMTHost: Leah DeLeon Learn More What did you think of this podcast? Share your opinions with us in this short feedback survey.Provide Feedback Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.https://ehaedu.org/Campus Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/Facebook: https://e-h-a.link/facebookLinkedIn: https://www.linkedin.com/company/eha/Email us: education@ehaweb.orgSubscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Get EHA Unplugged summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
A Shot in the Arm Podcast
Ben Plumley
Vet Rounds
Dr Sandy Karl CertAVP ECC
Health Discovered
Doctors explore surprising stories to uncover insights about health and well-being.
Out of the Gray (Gy) - Standard Imaging
Conversations with experts in radiation oncology exploring advancements in technology, research, and clinical practice.
Invictus Reviews
Emergency medicine board exam prep with Mel Herbert and team, covering core topics for all levels.
BetterHealthGuy Podcast
Conversations with experts on chronic illnesses, mold toxicity, Lyme disease, and integrative approaches to recovery.
Huberman Lab
Explores neuroscience and science-based tools for understanding and improving brain function, behavior, and health.
Paul Saladino MD podcast
A physician explores the root causes of chronic disease and optimal health through science and personal experimentation.
Cultivating H.E.R. Space: Uplifting Conversations for the Black Woman
Black women discuss healing, empowerment, and resilience through honest weekly talks on health, relationships, and personal growth.
This Podcast Will Kill You
Two epidemiologists explore the science, history, and impact of diseases and medical mysteries, one deadly topic at a time.
Pathogen Perspectives
pathogenperspectives
The Curbsiders Internal Medicine Podcast
Expert-led internal medicine discussions with clinical insights and humor for primary care and hospital medicine providers.
About EHA Unplugged
In these EHA-produced podcasts, experts share with you their hematology knowledge and stories. With "EHA Unplugged" we would like to give you the opportunity to unplug from your computer screen, while still learning, by listening to interviews, clinical cases, monologues, and more.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from EHA Unplugged in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's EHA Unplugged daily summary?
It's a free AI-powered email that summarizes new episodes of EHA Unplugged as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the EHA Unplugged podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official EHA Unplugged product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by European Hematology Association.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
How often does EHA Unplugged release new episodes?
EHA Unplugged publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does EHA Unplugged cover?
EHA Unplugged covers topics including Science, Medicine, Fitness, Health & Fitness, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting EHA Unplugged summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.